Webinar Live Date: Sept 1st, 2026 12:00pm EST
This free webinar guides clinical laboratories through the practical steps of moving from traditional workflows to digital pathology. Attendees will learn how to plan a successful rollout, choose systems that meet clinical and operational needs, and avoid common implementation challenges. Dr. Ehsan, Medical Director and CEO of CorePath Laboratories, will share lessons from his lab, which has already completed the transition with Roche and PathAI. Dr. Eric Walk, Chief Medical Officer of PathAI, will share an overview of PathAI and the shared vision with Roche to deliver a seamless, next-generation digital pathology experience now as one company.
Learning Objectives
|
Featured Speakers
Dr. Aamir Ehsan is a nationally recognized pathologist, educator, innovator, and health care entrepreneur whose career bridges diagnostic excellence, innovation and health care leadership. Board certified in Anatomic & Clinical Pathology, Hematopathology, Molecular Genetics, and Transfusion Medicine, he brings a rare combination of deep expertise and strategic vision insight to audiences across academic, private and industry settings. In 2009, Dr. Ehsan founded CorePath Laboratories, an early-stage entrepreneurial venture that combined the best of private and academic business models. Since 2009, it has grown into one of the nation’s fastest rising anatomic and hematopathology diagnostics reference labs.
Dr. Eric Walk is Chief Medical Officer at PathAI in Boston, MA. He is head of the Medical group, overseeing the Precision Medicine, Clinical Science, Quality and Regulatory teams. Eric has over 20 years of experience in precision medicine, oncology drug development and IVD companion diagnostics development. Prior to joining PathAI, he was Chief Medical and Scientific Officer at Roche Tissue Diagnostics/Ventana Medical Systems, where he led Medical & Scientific Affairs, overseeing the validation and FDA clearance/approval of multiple 510k and PMA IVD assays, companion diagnostics and digital pathology algorithms. Eric began his industry career at Novartis Oncology, where he held positions in Early Clinical Development and Translational Medicine, working to implement biomarker and precision medicine strategies for early and late stage targeted oncology therapeutics.
